RhumbLine Advisers’s Adamas Pharmaceuticals, Inc. ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-36,710
| Closed | -$106K | – | 3146 |
|
|
2020
Q1 | $106K | Sell |
36,710
-610
| -2% | -$1.76K | ﹤0.01% | 2768 |
|
|
2019
Q4 | $141K | Buy |
37,320
+154
| +0.4% | +$582 | ﹤0.01% | 2831 |
|
|
2019
Q3 | $190K | Buy |
37,166
+2,974
| +9% | +$15.2K | ﹤0.01% | 2762 |
|
|
2019
Q2 | $212K | Buy |
34,192
+5,084
| +17% | +$31.5K | ﹤0.01% | 2770 |
|
|
2019
Q1 | $207K | Sell |
29,108
-673
| -2% | -$4.79K | ﹤0.01% | 2738 |
|
|
2018
Q4 | $254K | Buy |
29,781
+9,514
| +47% | +$81.1K | ﹤0.01% | 2619 |
|
|
2018
Q3 | $406K | Sell |
20,267
-625
| -3% | -$12.5K | ﹤0.01% | 2364 |
|
|
2018
Q2 | $540K | Buy |
20,892
+5,525
| +36% | +$143K | ﹤0.01% | 2275 |
|
|
2018
Q1 | $367K | Buy |
15,367
+455
| +3% | +$10.9K | ﹤0.01% | 2352 |
|
|
2017
Q4 | $505K | Sell |
14,912
-2,441
| -14% | -$82.7K | ﹤0.01% | 2225 |
|
|
2017
Q3 | $367K | Buy |
17,353
+190
| +1% | +$4.02K | ﹤0.01% | 2468 |
|
|
2017
Q2 | $300K | Sell |
17,163
-2,309
| -12% | -$40.4K | ﹤0.01% | 2556 |
|
|
2017
Q1 | $341K | Buy |
19,472
+1,619
| +9% | +$28.4K | ﹤0.01% | 2441 |
|
|
2016
Q4 | $302K | Sell |
17,853
-140
| -0.8% | -$2.37K | ﹤0.01% | 2490 |
|
|
2016
Q3 | $295K | Buy |
17,993
+300
| +2% | +$4.92K | ﹤0.01% | 2492 |
|
|
2016
Q2 | $268K | Sell |
17,693
-394
| -2% | -$5.97K | ﹤0.01% | 2595 |
|
|
2016
Q1 | $262K | Buy |
18,087
+3,920
| +28% | +$56.8K | ﹤0.01% | 2602 |
|
|
2015
Q4 | $401K | Buy |
14,167
+530
| +4% | +$15K | ﹤0.01% | 2388 |
|
|
2015
Q3 | $228K | Buy |
13,637
+807
| +6% | +$13.5K | ﹤0.01% | 2711 |
|
|
2015
Q2 | $336K | Buy |
+12,830
| New | +$336K | ﹤0.01% | 2581 |
|